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Abstract 
Glioblastoma is characterized by high expression levels of pro-angiogenic cytokines and 
microvascular proliferation, highlighting the potential value of treatments targeting 
angiogenesis. Antiangiogenic treatment likely achieves a beneficial impact through 
multiple mechanisms of action. Ultimately, however, alternative pro-angiogenic signal 
transduction pathways are activated leading to the development of resistance, even in 
tumors that initially respond. The identification of biomarkers or imaging parameters to 
predict response and to herald resistance is of high priority. Despite promising phase 2 
clinical trial results and patient benefit in terms of clinical improvement and longer 
progression-free survival, an overall survival benefit has not been demonstrated in 4 
randomized phase 3 trials of bevacizumab or cilengitide in newly diagnosed 
glioblastoma or cediranib or enzastaurin in recurrent glioblastoma. However, future 
studies are warranted: predictive markers may allow appropriate patient enrichment, 
combination with chemotherapy may ultimately prove successful in improving overall 
survival, and novel agents targeting multiple pro-angiogenic pathways may prove 
effective. 
  
Introduction 
Glioblastoma, the most common primary malignant brain tumor, affects more than 
3/100,000 individuals each year. Median survival is below one year in population-based 
studies. Older age and lower performance status are associated with less aggressive 
care and shorter survival. The current standard of care includes maximal safe resection 
followed by radiotherapy plus concomitant and adjuvant chemotherapy with 
temozolomide. Elderly patients, i.e. patients > 65-70 years, not considered candidates 
for combined chemotherapy and radiation, mainly on the basis of comorbidities or 
impaired performance status, may be treated with radiation or temozolomide alone 
based on the promoter methylation status of O6-methylguanine DNA methyltransferase 
(MGMT), a mediator of resistance to alklyating chemotherapy drugs:  : in patients with 
tumors lacking MGMT promoter methylation radiotherapy alone is acceptable whereas 
in patients with MGMT promoter methylation temozolomide with or without radiation is 
acceptable (1). 
Angiogenesis has emerged as a primary target of drug development for 
glioblastoma over the last decade. This development was triggered by the disappointing 
outcomes with cytotoxic drugs and the recognition that the extensive pathological 
vascularization should make this disease potentially susceptible to antiangiogenic 
therapy. Bevacizumab, a humanized antibody to vascular endothelial growth factor 
(VEGF), received accelerated approval for recurrent glioblastoma in the United States 
(US) and many other countries based on radiographic response rates(2, 3). In contrast, 
because of the lack of a controlled trial bevacizumab did not receive approval in the 
European Union (EU), resulting in different standards of care between the US and the 
EU. Although randomized trials in newly diagnosed glioblastoma patient have not 
demonstrated an overall survival benefit, the final status of bevacizumab in this setting 
has yet to be fully determined, as well be discussed subsequently. Other VEGF-
targeting agents either have been or will continue to be explored in glioblastoma(4). 
Mechanisms of Action and Resistance 
The mechanisms of action of antiangiogenic therapies for solid tumors are multiple and 
may act in concert to delay tumor progression and ultimately prolong survival in several 
cancers. Folkman originally hypothesized that antiangiogenic agents confer an 
antitumor effect through induction of endothelial cell apoptosis, inhibition of new blood 
vessel growth, obliteration of small vessels, and decreased tumor perfusion, culminating 
in decreased delivery of oxygen and nutrients (“tumor starvation”) (5). However, during 
the initial stages of treatment, antiangiogenic agents may transiently “normalize” 
abnormal tumor vasculature by reducing blood vessel diameter and permeability which 
paradoxically improves tumor perfusion, reduces interstitial pressure, and improves 
tumor oxygenation(6-8), potentially sensitizing for radiotherapy and increasing tumor 
exposure to cytotoxic chemotherapy (Fig. 1)(7). Antiangiogenic therapy may also 
prevent VEGF-mediated vascular regrowth following endothelial cell injury after 
genotoxic therapies(9-11). Antiangiogenic agents may exhibit intrinsic antitumor activity, 
e.g., against glioblastoma stem-like cells (GSC) residing in the perivascular niche(12, 
13). Antiangiogenic agents may interfere with VEGF-mediated recruitment of tumor-
infiltrating VEGFR1 expressing monocytes(14). There is a potential role for 
antiangiogenic therapy in augmenting host immunity by reducing VEGF-mediated 
immune suppression(15) thereby improving the efficacy of immunotherapy(16). The 
relative importance of these multiple mechanisms of action regarding the therapeutic 
benefit of antiangiogenic therapy is unknown and different mechanisms may be 
operative in distinct subsets of patients as well as at different stages of the disease. 
The realization that antiangiogenic therapies provide transient clinical benefit and 
delay tumor progression prior to inevitable tumor progression has prompted an effort to 
better understand mechanisms of resistance to this class of therapeutic agent, as 
discussed subsequently. High rates of radiographic response rates and decrease in 
cerebral edema indicate a reduction in vascular permeability due to interruption of 
VEGF-A (originally termed vascular permeability factor) signaling(3, 6, 17). However, a 
lack of antitumor effect observed in some orthotopic rodent xenograft models of 
glioblastoma(18) suggests that angiogenesis inhibitors, e.g., cediranib, have limited 
intrinsic antitumor activity and that their main benefit may be limited to reductions in 
permeability and vasogenic cerebral edema(3, 6, 17). Notwithstanding a better 
understanding of the potential benefits of utilizing an optimal dose, schedule and drug 
combination, data from phase 3 clinical trials(19, 20) of bevacizumab suggest that some 
glioblastomas may be intrinsically resistant to antiangiogenic therapy. Inherent vessel 
insensitivity to the effect of VEGF inhibition could partially mediate this intrinsic 
resistance(21). Several adaptive resistance mechanisms may counteract any potential, 
initial benefit afforded by antiangiogenic therapy (Fig. 2). In the setting of VEGF 
signaling inhibition the tumor and its microenvironment release alternative pro-
angiogenic growth factors to promote VEGF-independent angiogenesis(22-24) which 
may be further augmented by the recruitment of pro-angiogenic myeloid cells such as 
monocytes, M2-skewed macrophages, granulocytes and myeloid-derived suppressor 
cells(14, 25, 26). Additionally, functional vessels are characteristically covered with 
pericytes which may protect endothelial cells from apoptosis in the face of VEGF 
blockade. Finally, adaptive resistance has been characterized by a transition to a 
mesenchymal and more invasive tumor phenotype(27-29). In the setting of 
antiangiogenic therapy, glioblastoma cells co-opt normal blood vessels(30) as a route of 
invasion into the surrounding brain. Although initial reports implied that anti-VEGF 
therapies were associated with non-enhancing radiographic tumor progression(31) 
originally interpreted as an increase in tumor invasion, subsequent reports did not 
support this observation(19, 20, 32, 33). 
Clinical Trials 
Clinical trials evaluating antiangiogenic agents for glioblastoma initially lagged behind 
other cancer indications due to concern of potentially serious adverse events in brain 
tumor patients, notably intracranial hemorrhage or stroke. However, early clinical 
experience confirmed the rarity of such events and that the toxicity profile of 
antiangiogenic agents for glioblastoma was not significantly different from that in other 
cancer indications; thereafter, clinical study of antiangiogenic agents for glioblastoma 
accelerated. A multitude of antiangiogenic agents have been evaluated for glioblastoma 
including tyrosine kinase inhibitors(34-49), monoclonal antibodies against VEGFR, and 
a soluble decoy receptor(50) (Table 1). Since clinical development is most advanced for 
bevacizumab, we focus herein on the design, results and conclusions of the major 
bevacizumab trials for glioblastoma. 
Bevacizumab for recurrent glioblastoma 
Dramatic overall radiographic response (ORR) rates and reassuring safety data led to 
two phase II studies which subsequently became the basis of the US Food and Drug 
Administration accelerated approval of bevacizumab as monotherapy for recurrent 
glioblastoma in 2009 (Table 2)(51). Of note, both studies compared outcome to 
historical benchmarks and included independent radiologic review. The BRAIN study 
randomized patients to bevacizumab (n=85) or bevacizumab plus irinotecan (n=82) but 
was not designed to detect differences between the two treatment arms(3). Outcomes 
for the bevacizumab and bevacizumab plus irinotecan arms included ORR rates of 
28.2% and 37.8%, PFS-6 rates of 42.6% and 50.3% and median overall survival (OS) of 
9.2 and 8.7 months, respectively. A single-arm study of bevacizumab among 48 
patients treated at the US National Cancer Institute (NCI) noted ORR and PFS-6 rates 
of 35% and 29%, respectively, and a median OS of 7.75 months(2). Although the 
BRAIN and NCI trials generated unprecedented ORR and PFS-6 rates the European 
Medicines Agency declined to approve bevacizumab for recurrent glioblastoma due to 
the absence of a non-bevacizumab control arm, a modest OS increment versus 
historical controls, inadequate elucidation of true antitumor effect, and challenges with 
radiographic response assessment(52). 
Thereafter, attempts to augment the benefit of single-agent bevacizumab 
included studies evaluating bevacizumab combined with chemotherapeutics(31, 53-62), 
targeted therapies(63-65) and re-irradiation(66-68). Unfortunately all of these 
combinatorial regimens failed to improve outcome beyond that of bevacizumab 
monotherapy could be due to a decrease of drug delivery to the tumor(8). A single 
exception is a phase II study in which 148 recurrent GBM patients randomized to 
lomustine, bevacizumab or lomustine plus bevacizumab (Table 2)(69). Outcome was 
notably improved for the combination arm including PFS-6 of 41%, compared to 11% 
and 18% for lomustine and bevacizumab alone, respectively. The combination arm was 
also associated with improved overall survival at 9 months (OS9), the primary endpoint 
of this trial. The OS9 was 59% for the combination arm and 43% and 38% for lomustine 
and bevacizumab alone, respectively. Two aspects of this study warrant special 
comment. First this is the only study to date that incorporates a comparative, 
randomized statistical design with a non-bevacizumab control arm with minimal 
crossover to bevacizumab. Second, it is the first study to report a bevacizumab 
combination with improved outcome compared to bevacizumab monotherapy. Yet, the 
bevacizumab alone arm underperformed in this trial, and the differences between PFS 
and OS in all arms suggest that further interventions had a great impact on outcome in 
this trial. An ongoing phase III study to further evaluate these findings (EORTC 26101, 
NCT01290939) randomizes recurrent glioblastoma patients to lomustine or lomustine 
plus bevacizumab with a primary endpoint of OS. 
Resistance to bevacizumab inevitably develops and such patients typically die 
rapidly due to ineffective therapies(2, 31, 54, 70-73). Retrospective data suggests that 
bevacizumab continuation beyond initial progression may modestly improve 
outcome(74). Prospective evaluation of this approach is forthcoming via an ongoing trial 
(TAMIGA). Nonetheless, effective therapies for bevacizumab refractory glioblastomas 
are desperately needed. 
Bevacizumab for newly diagnosed glioblastoma 
Initial single arm, phase II studies of bevacizumab in combination with temozolomide 
and radiation for newly diagnosed glioblastoma patients noted a near doubling of 
median PFS to 13-14 months compared to historical benchmarks and a nominal median 
OS increment to 20 months(75-77). Two randomized, placebo-controlled phase III 
studies, RTOG 0825 and AVAglio, reported extension of PFS but no difference in OS 
(Table 2)(78, 79). Specifically, median PFS was 47-71% longer for bevacizumab 
recipients compared to controls, but OS was not significantly different in the two 
treatment arms. Since 30-40% of controls on each study received bevacizumab at 
progression, crossover is a potential confounder in terms of the impact on OS, although 
this remains a matter of speculation. Importantly, both studies assessed pre-defined 
clinical and molecular prognostic factors for association with outcome but failed to 
identify any of these patient subgroups more or less likely to benefit from bevacizumab; 
however, there is ongoing investigation in both trials to determine whether more 
complex genetic signatures may define subgroups more likely to benefit from 
bevacizumab in combination with chemoradiation, as discussed below and elsewhere. 
Both RTOG 0825 and AVAglio assessed other measures of clinical benefit. 
AVAglio noted preserved Karnofsky performance status and lower corticosteroid 
requirement among bevacizumab recipients. Unexpectedly, results from validated 
measures of quality of life (QOL) including the EORTC QLQ-C30 and BN20 
questionnaires that were incorporated by both studies yielded conflicting results. Among 
bevacizumab recipients, consistently improved QOL scores were reported across five 
prospectively defined domains on AVAglio, while lower scores were noted for several 
domains on RTOG 0825. Moreover, in RTOG 0825 symptom burden was increased in 
the bevacizumab arm versus the control arm using the MDASI-BT.  The explanation for 
these discordant results remains unclear. Investigators in RTOG 0825 assessed 
radiographic response solely by enhancing tumor (Macdonald criteria(80)) and may 
have failed to identify early progression among bevacizumab recipients. In contrast, 
AVAglio assessed both enhancing and non-enhancing tumor (RANO criteria)(81). 
RTOG 0825, but not AVAglio, incorporated formal neurocognitive testing and noted 
diminished processing speed and executive function among bevacizumab recipients 
compared to controls. These notable findings warrant follow-up investigation. In 
summary, clinical trial data to date support improved PFS but lack of significant OS 
benefit with bevacizumab among recurrent and newly diagnosed glioblastoma patients. 
Biological and Imaging Markers 
The increased understanding of the molecular profile of glioblastoma suggests that 
subgroups of these patients may respond differentially to distinct classes of 
antiangiogenic agents. There are a number of tumor tissue and circulating candidate 
biomarkers for predicting the efficacy of antiangiogenic agents. Tumor tissue 
biomarkers that have been assessed, but not confirmed(79, 82) include a 9-gene 
signature representative of the mesenchymal subtype of glioblastoma(83, 84), VEGF 
expression(85, 86), O6-methylguanine methyltransferase promoter methylation 
status(79), epidermal growth factor receptor (EGFR), platelet-derived growth factor 
receptor a (PDGFR-a) and c-KIT for VEGFR2 inhibition(6, 87). Negative predictive 
markers for the use of bevacizumab in newly diagnosed glioblastoma include an 
expanded set of mesenchymal genes(82), whereas the proneural molecular (tumors 
with IDH mutations excluded) subtype of glioblastoma specifically benefitted from 
bevacizumab(86) versus the other three cancer genome atlas (TCGA) glioblastoma 
moelcular subtypes. Independent, e.g. cross-trial confirmation of these putative 
predictive markers is needed, and their use in current clinical practice should be 
discouraged. 
Circulating cytokines are attractive candidate biomarkers. However, in the 
AVAglio trial pretreatment plasma VEGF and sVEGFR2 levels were not associated with 
PFS or OS(20, 86, 88). Matrix metalloproteinase (MMP)-2 is a plasma candidate 
biomarker for efficacy of bevacizumab(89). Elevated soluble VEGFR1, a negative 
regulator of the VEGF signaling cascade, has been proposed as a resistance biomarker 
in other solid tumor types(90). 
Radiographic response as defined by a reduction in tumor contrast-enhancement 
on brain CT or MRI scans may not reflect intrinsic antitumor activity since 
antiangiogenic treatment notably targeting VEGF signaling may rapidly reduce vessel 
permeability and contrast extravasation. This rapid and usually transient radiographic 
change is sometimes termed “pseudoresponse.” Consequently, antiangiogenic 
treatments have compelled a focus on brain tumor imaging leading to the introduction of 
novel, candidate techniques to accurately define tumor response and tumor 
progression. Some of these MRI methods include apparent diffusion coefficient 
(ADC)(91), dynamic contrast-enhanced (DCE) and dynamic susceptibility-contrast 
(DSC) techniques to assess baseline and dynamic features of glioblastoma 
vasculature(92, 93), as well as vessel architectural imaging (VAI) that exploits a 
temporal shift in the magnetic resonance signal, forming the basis for vessel caliber 
estimation(94). VAI techniques demonstrate vessel-normalizing microcirculation during 
VEGF inhibition with cediranib, a pan-VEGF receptor tyrosine kinase inhibitor(94). The 
T1-derived parameter KTrans may reflect not only vessel normalization but also efficacy 
with VEGF inhibition. Cerebral blood flow may increase early after initiation of anti-
VEGF therapy, identify responders, and is associated with improved tumor oxygenation 
status(87). Dopamine and amino acid positron emission tomography (PET) has been 
evaluated as an early imaging parameter of response to anti-VEGF therapy(95, 96). 
Further assessment of these imaging techniques and implementation of uniform 
imaging protocols in prospective, randomized trials is essential to determine their 
ultimate predictive value. 
Future Directions 
Significant effort and investment have been dedicated to the development of 
antiangiogenic therapies for glioblastoma. Consequently, new criteria for the 
assessment of disease by neuroimaging have been defined(81), new concepts of 
clinical trial design have been developed(97) and the quality of clinical trial design, 
conduct and analysis have been improved(20, 79, 98). Nevertheless, an overall survival 
benefit has yet to be identified after five randomized phase 3 trials in the newly 
diagnosed and recurrent glioblastoma setting. Where do we go from here? 
First, future, pivotal, phase 3 trials of antiangiogenic agents should be conducted 
on the basis of data from well-designed, placebo-controlled, randomized, phase 2 trials 
when feasible(97). Second, it is highly likely that a future survival advantage is likely to 
come from the combination of antiangiogenic and cytotoxic treatments, similar to other 
solid tumor types. As noted, the only positive OS data from a randomized (phase 2) trial 
was observed for recurrent glioblastoma with chemotherapy plus bevacizumab. Third, 
although striking differences in patient response to and duration of benefit from VEGF 
inhibitors among patients with glioblastoma have been observed, none of the promising 
neuroimaging, histological and circulating markers associated with radiographic or 
clinical benefit have yet been validated. This until now missed opportunity of drug 
development is equally unfortunate for the field of neuro-oncology and for the 
pharmaceutical industry and even more for patients who may derive benefit from this 
treatment approach. Thus, intensive effort should focus on the identification and 
validation of such predictive markers. Fourth, with improved cellular and rodent glioma 
models including patient-derived and stem-like cell models and feasible animal imaging 
techniques available, more preclinical studies focusing on predictive biomarkers and 
mechanisms of escape are feasible and should supplement the ongoing efforts of 
moving antiangiogenic agents forward. 
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Table 1. Representative clinical trials of VEGF/VEGFR targeting therapeutics among 
recurrent glioblastoma patients 
 
Agent Mechanism Dose # 
Patients
ORR
(%) 
PFS-6 
(%) 
OS 
(median, 
months) 
Reference
Aflibercept Soluble 
decoy 
VEGFR 
4 mg/kg 
biweekly 
42 18 7.7 9.8 50 
Cediranib VEGFR TKI 30 mg daily 118 15.3 16 8.0 98 
Nintedanib  VEGFR TKI 200 mg 
twice a day
13 0 4 8.1 48 
Pazopanib VEGFR TKI 800 mg 
daily 
35 5.7 3 8.8 34 
Pazopanib (+ 
lapatinib) 
VEGFR TKI 400 mg 
daily 
41 5 7.5 NR 47 
Sorafenib (+ 
daily TMZ)  
VEGFR TKI 400 mg 
daily 
32 3 9.4 10.4 35 
Sunitinib VEGFR TKI 37.5 mg 
daily 
32 10 10.4 9.4 42 
Vandetanib  VEGFR TKI 300 mg 
daily 
32 12.5 6.5 6.3 41 
Bevacizumab Humanized 10mg/kg 85 28 43 9.3 3 
anti-VEGF 
mAb 
biweekly 
Abbreviations: kg, kilogram; mAb, monoclonal antibody; mg, milligram; ORR, overall 
radiographic response; OS, overall survival; PFS-6, progression-free survival at six 
months; TKI, tyrosine kinase inhibitor; TMZ, temozolomide; VEGF, vascular endothelial 
growth factor; VEGFR, vascular endothelial growth factor receptor.  
  
Table 2. Landmark clinical trials of bevacizumab for glioblastoma (GBM) 
Trial Regimen # 
Patients
Median PFS 
(months) 
PFS-6 
(%) 
Median 
OS 
(months) 
Reference 
RECURRENT GBM 
BRAIN BEV 85 4.2 42.6 9.2 3 
BRAIN BEV + 
irinotecan 
82 5.6 50.3 8.7 3 
NCI BEV 48 4.0 29 7.8 2 
BELOB BEV 50 3 18 8 69 
BELOB Lomustine 46 2 11 8 69 
BELOB BEV + 
lomustine 
44 11 41 11 69 
NEWLY DIAGNOSED GBM 
RTOG 
0825 
BEV + 
TMZ/XRT 
312 10.7 (HR: 
0.79; 
p=0.007) 
NR 15.7 79 
RTOG 
0825 
TMZ/XRT 309 7.3 NR 16.1 79 
AVAGlio BEV + 
TMZ/XRT 
458 10.6 
(HR:0.64, 
p<0.0001) 
NR 16.9 78 
AVAGlio TMZ/XRT 463 6.2 NR 16.8 78 
Abbreviations: BEV, bevacizumab; HR, hazard ratio; NCI, National Cancer Institute, 
USA; NR, not reported; OS, overall survival; PFS-6, progression-free survival at six 
months; TMZ, temozolomide; XRT, radiation therapy. 
  
Figure 1. Normalization of tumor vasculature. (A) Tumor vasculature is structurally and 
functionally abnormal. One potential mechanism of action for antiangiogenic therapies is 
transient improvement in both the structure and the function of tumor vessels. However, 
sustained antiangiogenic treatment may eventually result in a vasculature that is both 
resistant to further treatment and inadequate for the delivery of drugs or oxygen. (B) 
Vessel structural patterns before, during and with sustained VEGFR2 blockade. (C) 
Diagram depicting the concomitant changes in pericyte coverage (green) and basement 
membrane thickness (blue) before, during and with sustained VEGFR2 blockage. (D) 
Changes in the balance of pro- and antiangiogenic factors leading to the phenotypic 
changes noted above. Reprinted from Jain (99). 
 
Figure 2. Intrinsic and evasive tumor resistance to antiangiogenic agents. Some GBM 
patients do not respond to antiangiogenic therapies (intrinsic resistance). However, in 
patients who initially benefit, the treatment induces evasive resistance pathways, which 
bypass the angiogenic blockade. Pro-angiogenic and non-enhancing/infiltrative tumor 
growth patterns predominate following initial antiangiogenic response in GBM. Pro-
angiogenic evasion results from activation of alternate pro-angiogenic factors or 
recruitment of BMDCs to promote VEGF-independent neovascularization. A more 
infiltrative growth pattern is observed in pro-invasive evasion. GBM stem-like cells may 
survive or be enriched by antiangiogenic therapy. BMDC: Bone marrow-derived cell; 
EPC: Endothelial progenitor cell; FLAIR: Fluid-attenuated inversion recovery; GBM: 
Glioblastoma; GSC: Glioblastoma stem cell; MMP: Matrix metalloproteinase; PPC: 
Pericyte progenitor cell; SDF-1α: Stromal-derived factor-1α. Reprinted from Lu and 
Bergers (24). 
